| Name | Title | Contact Details |
|---|
At The Portland Clinic, we’ve been treating the people in our community with trust, kindness and understanding for nearly 100 years. For us, that means asking good questions and paying close attention to your answers. Working hard to find out where you...
Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company developing innovative ways to treat inflammatory and immune-related diseases. Our most advanced drug candidate is EB05 (paridiprubart), a monoclonal antibody developed for acute and chronic disease indications that involve dysregulated innate immune responses. Edesa is currently evaluating EB05 in a Phase 3 study as a potential treatment for Acute Respiratory Distress Syndrome (ARDS), a life-threatening form of respiratory failure. In addition, Edesa is developing an sPLA2 inhibitor, EB01, as a topical treatment for chronic Allergic Contact Dermatitis (ACD), a common occupational skin condition. The company has also received regulatory approval to conduct a Phase 2 trial its EB06 monoclonal antibody as a treatment for vitiligo, a life-altering autoimmune disease that causes skin to lose its color in patches. We also are planning a future Phase 2 study of paridiprubart for systemic sclerosis (scleroderma), an autoimmune rheumatic disorder that causes fibrosis (scarring/hardening) of skin and internal organs.
SpaLab, Inc. is a San Marcos, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Custom coater, converter and packager for the medical, electronics, automotive and general industrial markets.
Commonwealth Biotechnologies is a Richmond, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.